GT Biopharma, Inc. — filing summary
Filing identity: The supplied filing is for OXIS International, Inc., not GT Biopharma, Inc. It is a Form 10-K for the fiscal year ended December 31, 2012, signed November 17, 2014. The summary below reflects the filing as provided; confirm the company and period before relying on it.
Business context and reporting period
OXIS described a transition from diagnostic and research assay businesses toward nutraceutical and cosmeceutical products, principally using its ergothioneine ingredient, EGT. It also discussed potential licensing of proprietary compounds and a cannabinoid-focused subsidiary, Oxis Biotech. Operations and sales remained limited, and the company relied heavily on outside consultants and financing.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $342,000 | $26,000 |
| Cost of product revenue | $94,000 | $48,000 |
| Gross profit (loss) | $248,000 | $(22,000) |
| Operating expenses | $3,762,000 | $3,906,000 |
| Operating loss | $(3,514,000) | $(3,928,000) |
| Interest expense | $1,653,000 | $556,000 |
| Net loss | $(5,171,000) | $(3,700,000) |
| Net cash used in operating activities | $(987,000) | $(963,000) |
| Cash at year-end | $123,000 | $92,000 |
FY 2012 gross margin was approximately 72% of revenue, versus a gross loss in 2011. Revenue increased sharply from a small base, primarily from ErgoFlex direct-mail sales; management cautioned that the limited marketing activity made the year-over-year revenue comparison a poor indicator of future performance. The company reported a $6.36 million working-capital deficit, $6.56 million in current liabilities, and an accumulated deficit of approximately $88.97 million at year-end. Total assets were $226,000.
Operating cash use was largely offset by $930,000 of note proceeds and $90,000 of minority-interest funding; cash increased by $31,000. At year-end, the company had $1.38 million of warrant liability and convertible debt balances, including current and noncurrent debentures. A December 2012 loan included an initial $315,000 borrowing, carried 18% annual interest, was secured by company assets on a junior basis to existing liens, and matured in May 2013. The filing also describes a $1.12 million settlement obligation to Bristol and Merit, partly paid in shares and partly in notes.
Material changes versus the prior year
- Revenue rose by $316,000, while cost of product revenue rose by $46,000. Operating expenses declined by $144,000, but the operating loss remained substantial.
- Net loss increased by $1.47 million, reflecting higher interest expense and a less favorable year-over-year effect from warrant and derivative remeasurement. The financial-statement presentation of the warrant/derivative change is not fully clear: MD&A describes a $94,000 gain in 2012, while the statement of operations shows a negative $94,000 amount.
- Common shares outstanding increased from 269.3 million at December 31, 2011 to 500.6 million at December 31, 2012, primarily through debt conversions and shares issued for services. The filing reports 635.8 million warrants outstanding at year-end 2012.
- R&D spending fell from $17,000 to zero. The filing attributes lower SG&A partly to reduced staffing, while advertising and promotional expenses increased to $400,000 from $158,000.
Outlook, risks, contingencies, and unusual items
- Going concern: The auditor and management cited substantial doubt about the company’s ability to continue as a going concern, due to recurring losses, limited cash, and dependence on future financing. The statements contain no adjustments for a possible inability to continue operations.
- Outlook: Management expected revenue to increase in 2013 if sufficient capital could be raised and planned additional consumer products. It also described skin-care products targeted for release in late 2014 and potential future fundraising of $5 million for an expanded Oxis Biotech strategy. These were plans, not assurances.
- Financing and dilution: Funding relied on convertible debentures, warrants, and share issuance, including instruments with anti-dilution provisions and conversion prices as low as $0.01. The filing also reports substantial subsequent financings through 2014; these post-period events should not be confused with FY 2012 results.
- Controls and governance: Management concluded that disclosure controls and internal control over financial reporting were ineffective at December 31, 2012, citing inadequate segregation of duties and risk of executive override. The filing says a full-time CFO was hired in November 2014. None of the three directors was considered independent.
- Business and regulatory risks: Products were at an early commercialization stage in competitive markets; the company had limited staff, outsourced manufacturing, and faced FDA, FTC, labeling, advertising, and product-quality requirements. The filing’s Risk Factors section is omitted under the smaller-reporting-company rules, so it does not provide a full risk-factor discussion here.
- Other items: A 2014 licensing dispute was settled for a cash payment and a perpetual royalty on future product sales; the filing does not state the payment amount. The auditor’s opinion on the financial statements was unqualified, but it did not express an opinion on internal-control effectiveness.
Most important facts for investors to verify
- Confirm that this OXIS International filing is the intended company and that FY 2012—not a different reporting period—is the subject of the request.
- Review the complete audited statements and debt notes to establish the amount, maturity, collateral, default status, and subsequent settlement or repayment of obligations.
- Reconcile the warrant and derivative fair-value presentation, including the conflicting description of the 2012 $94,000 change.
- Assess actual subsequent financing, share issuance, conversion terms, warrant overhang, and the resulting dilution; the filing reports 591.7 million shares outstanding as of October 2014.
- Verify whether planned product launches, licensing revenues, and the stated cash runway or fundraising plans were achieved; the filing provides no assurance that they would be.